DUBLIN – The constellation of therapeutic development and tools companies that has grown out of the work of two CRISPR/Cas9 co-inventors, Emmanuelle Charpentier and Jennifer Doudna, has entered a global intellectual property agreement under which each signatory will recognize the other's IP rights and IP licensing deals they have entered. The companies involved will also cooperate on maintaining the patent estate and will co-ordinate their efforts on prosecuting, defending and enforcing their shared IP rights.